NEW YORK (GenomeWeb News) – Definiens and Metamark Genetics today announced a multiyear agreement for use of Definiens' image analysis product for Metamark's prostate cancer prognostic test.
Under the terms of the deal, Definiens' Cognition Network Technology is being integrated with Metamark's ProMark test for the automatic classification of prostate tumor regions of interest and quantification of novel proteomic markers expressed in prostate biopsies.
Metamark plans to launch ProMark in early 2014 with a focus on pathologists and urologists. The test is designed to help physicians decide which prostate cancer patients may benefit from active surveillance instead of aggressive treatment and then make appropriate treatment decisions.
Financial and other terms of the deal were not disclosed.
In 2011, Definiens and Metamark announced a collaboration to develop and commercialize a multiplex platform to run prognostic and predictive assays for early stage cancers.